Gradient-degradable drug-loaded hemostatic sponge and preparation method thereof
By using a staggered degradable three-dimensional reticular hyaluronic acid hydrogel hemostatic cotton after sinus surgery, the problem of traditional hemostatic cotton cannot be administered slowly during degradation is solved, effectively hemostatic and mucosal repair is achieved, and better clinical effects and wider application range.
Patent Information
- Application Number
- CN202410972007.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-19
- Publication Date
- 2024-11-12
AI Technical Summary
The prior art is difficult to effectively and slowly release drugs to local areas for a long time after sinus surgery, and traditional hemostatic cotton cannot be slowly administered when degraded, and it is impossible to achieve effective hemostatic and mucosal repair at the same time.
Using a hierarchically degradable three-dimensional network hyaluronic acid hydrogel hemostatic cotton, a chemical or physical cross-linking process is prepared, and combined with sodium carboxymethyl starch and carboxyethyl cellulose to form a highly absorbent and The hemostatic cotton with sustained release characteristics can continuously and slowly release glucocorticoids in specific parts of the nasal sinus.
Effective hemostasis and mucosal repair after sinus surgery are achieved, while avoiding systemic side effects, providing better clinical effects and a wider range of applications.
Smart Images

Figure CN118924939A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of medical biomaterials, and in particular to a degradable hemostatic sponge with a drug delivery system and a preparation method thereof. Background Art
[0002] Chronic sinusitis (CRS) is a highly heterogeneous disease associated with chronic inflammation, characteristic cytokines, and mucosal remodeling patterns. The incidence of CRS in my country is about 8%, of which about 20% require surgical treatment, which has a serious impact on quality of life and socioeconomics. Endoscopic sinus surgery (ESS) is an effective minimally invasive surgical method for the treatment of CRS. Its purpose is to improve nasal drainage and ventilation, but it is often accompanied by complications such as epistaxis and nasal adhesion stenosis after surgery. Nasal packing is an effective measure to prevent these complications. Ideally, nasal packing biomaterials can reduce postoperative bleeding, promote healing, and reduce inflammation after ESS. However, although there are many biological filling materials that can support the structure of the middle nasal meatus after ESS, prevent postoperative bleeding, and promote wound healing, these products cannot improve mucosal inflammation.
[0003] Glucocorticoids have strong and multidirectional anti-inflammatory activity. Their anti-inflammatory treatment is a treatment method for the etiology of diseases such as CRS and allergic rhinitis and has Class Ia evidence-based medicine evidence. Glucocorticoids can reduce the hyperresponsiveness and vascular permeability of the sinus mucosa, play an anti-inflammatory role, prevent adhesion and scar formation, and have a therapeutic effect on polypoid changes in the mucosa around the sinus orifices and allergic inflammation of the mucosa. In addition, hyaluronic acid (HA) is a linear macromolecular mucopolysaccharide composed of two sugar units of alternating glucuronic acid and N-acetylglucosamine. It has good biocompatibility, biodegradability, high viscoelasticity, and can bind to specific receptors on the cell surface. HA can not only scavenge reactive oxygen free radicals, promote the proliferation and migration of keratinocytes, but also accelerate the epithelialization of the wounded mucosa. At the same time, the hyaluronic acid fragments produced by its degradation can also regulate the inflammatory response and stimulate angiogenesis. Hyaluronic acid filling after sinus surgery can help the nasal epithelial mucosa recover. When used in conjunction with glucocorticoids, it can significantly improve the recovery of the surgical mucosa and the clinical symptoms and signs of patients after sinusitis surgery.
[0004] Chronic sinusitis is a long-term chronic inflammation of the nasal and sinus mucosa, which requires long-term treatment. Systemic use of hormones can lead to multiple side effects. Due to the cilia of the nasal mucosa, the hormones in nasal sprays are difficult to remain on the surface of the nasal mucosa for a long time, and the nasal sprays cannot reach deep areas such as the frontal sinus. Compared with traditional local drug delivery methods such as nasal sprays, it is very necessary to develop a drug carrier hemostatic sponge that not only has a good hemostatic effect, but also has biocompatibility and a tailorable structural size. It can be placed in a specific part of the nasal cavity and sinuses to slowly release hormones to the local area for a long time. Summary of the invention
[0005] One advantage of the present invention is that it provides a step-by-step degradable drug-loaded hemostatic sponge and a preparation method thereof, which adopts a three-dimensional network structure, can deliver drugs, and has both hemostasis and drug treatment, thereby achieving a better therapeutic effect.
[0006] Another advantage of the present invention is that it provides a drug-loaded hemostatic sponge that can be degraded in stages and a preparation method thereof. The hemostatic material can be degraded rapidly, and the hydrogel component can be degraded slowly. This cascade degradation function allows the drug-loaded hemostatic sponge of the present invention to be administered slowly, thus solving the shortcoming of the traditional overall simultaneous degradation that cannot be administered slowly.
[0007] Another advantage of the present invention is that it provides a step-by-step degradable drug-loaded hemostatic sponge and a preparation method thereof, which has good biocompatibility, is suitable for being placed in specific parts of the nasal cavity and sinuses for long-term, continuous and slow release of drugs, is suitable for use by patients with sinusitis, and has both hemostatic and mucosal repair effects.
[0008] Another advantage of the present invention is that it provides a step-by-step degradable drug-loaded hemostatic sponge and a preparation method thereof, which has a reasonable structure and can be degraded in stages, and the degradation order can be selected according to usage requirements. Compared with traditional simultaneously degradable hemostatic sponges, it has better clinical effects.
[0009] Another advantage of the present invention is that it provides a step-by-step degradable drug-loaded hemostatic sponge and a preparation method thereof, which has good hemostatic effect, is harmless to the human body, has low cost, is easy to use, and is suitable for clinical promotion and application.
[0010] Another advantage of the present invention is that it provides a degradable hemostatic sponge and a preparation method thereof. The compressed version of the degradable nasal hemostatic sponge is small in size and can be cut, which is convenient for postoperative nasal sinus packing. In addition, dry starch is a capillary former and a hydrophilic substance with extremely strong water absorption. After absorbing water, it can expand to 300 times its original volume, which can generate a certain pressure on the surrounding wall of the sinus cavity and has a good hemostatic effect.
[0011] Another advantage of the present invention is that it provides a step-by-step degradable drug-loaded hemostatic sponge and a preparation method thereof, which has different drug-loading methods corresponding to different hormones such as mometasone glycolate, and can use chemical cross-linking or physical adsorption. Different methods increase its application range and make its application more extensive.
[0012] To meet at least one of the above advantages of the present invention, according to one aspect of the present invention, the present invention provides a method for preparing a drug-loaded hemostatic sponge that can be degraded stepwise, comprising the following steps:
[0013] (S10) preparing drug-loaded HA hydrogel;
[0014] (S20) preparing a hemostatic sponge composite structure pulp; and
[0015] (S30) preparing hemostatic sponge.
[0016] According to one embodiment, the step (S10) includes the following steps: (S101) preparing a drug-loaded hydrogel liquid A; and (S102) preparing a drug-loaded hydrogel mixed solution B with a three-dimensional network structure, wherein in the step (S102), the solution A is added to a sodium thiol hyaluronate solution, and the drug-loaded hydrogel B is prepared by self-crosslinking of thiol / disulfide bonds.
[0017] According to one embodiment, in the step (S101), polyethylene glycol is added to distilled water, and then mometasone furoate, fluticasone propionate or budesonide is added, and stirred under ultrasound until completely dissolved to obtain a drug-loaded hydrogel liquid A; wherein the step (S102) includes the following steps: (S0121) sodium hyaluronate is dissolved in distilled water and dissolved evenly under ultrasound; (S1022) solution A prepared in the step (S101) is added and stirred; (S1023) carbodiimide is added and magnetically stirred; and (S1024) stirring for a predetermined time to obtain a drug-loaded hydrogel mixed solution B through chemical crosslinking.
[0018] According to one embodiment, the step (S101) includes the following steps: (S1011) dissolving adipic acid dihydrazine (ADH) in a HA aqueous solution and adjusting the pH; (S1012) dissolving HA in distilled water, ultrasonically dispersing and adding the liquid prepared in the step (S1011); (S1013) adding 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC), and magnetically stirring to obtain a drug-loaded hydrogel liquid A through cross-linking; wherein the step (S102) includes the following steps: (S1021) dissolving poloxamer 407 (F127) and mometasone furoate (MF) in PBS, and stirring in an ice-water bath to obtain an F127-MF solution; (S1022) dissolving F127-MF in the drug-loaded hydrogel liquid A in the step (S1013), and magnetically stirring to obtain a drug-loaded hydrogel mixed solution B.
[0019] According to an embodiment of the present invention, the step (S10) includes the following steps: (S1001) preparing oxidized hyaluronic acid; (S1002) preparing HA-ADH; and (S1003) preparing HA@F127-MF hydrogel.
[0020] Wherein, in the step (S1001), HA is dissolved in deionized water to prepare a 1 wt% aqueous solution, and then NaIO4 is added to the solution, the solution is reacted in the dark, ethylene glycol is added to terminate the reaction, the solution is stirred, dialyzed, and freeze-dried to obtain oxidized hyaluronic acid (OHA); in the step (S1002), (A) adipic acid dihydrazide is dissolved in the aqueous solution of HA to prepare solution A; (B) 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) and 1-hydroxybenzotriazole are dissolved in deionized water and dimethyl The mixture is added to solution A, reacted, dialyzed, and freeze-dried to obtain a pure HA-ADH product. In the step (S1003), poloxamer 407 (F127) and mometasone furoate (MF) are dissolved in PBS, stirred and dissolved in an ice water bath to prepare an F127-MF solution, and then HA-ADH and OHA are dissolved in the F127-MF solution, respectively, to form a HA-ADH solution and an OHA solution, and the two solutions are mixed in a ratio of 1:1 to form a HA@F127-MF hydrogel.
[0021] The step (S20) comprises the following steps: (S201) dissolving sodium carboxymethyl starch and hydroxyethyl cellulose in distilled water; (S202) stirring evenly and pouring in liquid B; (S203) stirring to allow sodium carboxymethyl starch, carboxyethyl cellulose and hyaluronic acid to form a three-dimensional network structure of hemostatic cotton slurry, wherein in the step (S30), the slurry is packaged into plastic boxes, frozen at -20°C for 24 hours, freeze-dried at -50°C to -80°C under vacuum conditions, and compressed into a desired shape under a predetermined pressure.
[0022] The mass ratio of polyethylene glycol to mometasone furoate is 1:12, the mass ratio of sodium hyaluronate to polyethylene glycol is 1:1, the mass ratio of carbodiimide to sodium hyaluronate is 1:2, the mass ratio of sodium carboxymethyl starch to carboxyethyl cellulose is 9:5, and the mass ratio of carboxyethyl cellulose to mometasone furoate is 1:6.
[0023] According to another aspect of the present invention, the present invention also provides a cascade-degradable drug-loaded hemostatic sponge, which is a drug-loaded hyaluronic acid hydrogel hemostatic sponge and has a three-dimensional network structure, wherein the three-dimensional network structure is a hydrogel formed by cross-linking sodium hyaluronate, solution A, and carbodiimide for a predetermined time through magnetic stirring, or a drug-loaded hydrogel is made by self-crosslinking of thiol / disulfide bonds in thiol sodium hyaluronate, and the drug-loaded hydrogel is further compounded with sodium carboxymethyl starch and carboxyethyl cellulose to form a three-dimensional network composite structure pulp, wherein solution A is obtained by dissolving polyethylene glycol, distilled water, and mometasone furoate, fluticasone propionate or budesonide under ultrasound, or oxidized hyaluronic acid and HA-ADH are dissolved in F127-MF to form a solution, and then mixed with HA@F127-MF hydrogel. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] Figure 1 It is a schematic diagram of the stepwise degradable drug-loaded hemostatic sponge according to a preferred embodiment of the present invention.
[0025] Figure 2 Schematic diagram of the stepwise degradable drug-loaded hemostatic sponge according to the above preferred embodiment of the present invention and the hemostatic sponge currently on the market before absorbing liquid.
[0026] Figure 3 According to the schematic diagram of the stepwise degradable drug-loaded hemostatic sponge and the hemostatic sponge currently on the market in the above preferred embodiment of the present invention, water is preferentially added to the hemostatic sponge on the market as the control group.
[0027] Figure 4 According to the schematic diagram of the cascade-degradable drug-loaded hemostatic sponge and the hemostatic sponge currently on the market in the above preferred embodiment of the present invention, water was added to the cascade-degradable drug-loaded hemostatic sponge as the experimental group.
[0028] Figure 5 A schematic diagram showing a comparison between the stepwise degradable drug-loaded hemostatic sponge according to the above preferred embodiment of the present invention and the hemostatic sponge currently on the market after absorbing liquid.
[0029] Figure 6 and Figure 7 This is an electron microscope image of the stepwise degradable drug-loaded hemostatic sponge according to the above preferred embodiment of the present invention.
[0030] Figure 8 4 is a release curve diagram of mometasone furoate provided with the drug delivery system according to the above preferred embodiment of the present invention.
[0031] Fig. 9 is a curve chart of a cell proliferation experiment with the drug delivery system according to the above preferred embodiment of the present invention.
[0032] Fig.10This is the experimental surgical procedure of rats equipped with the drug delivery system according to the above preferred embodiment of the present invention.
[0033] Fig.11 It is a curve diagram of mometasone furoate concentration in sinus mucosa during animal experiment of the drug delivery system according to the above preferred embodiment of the present invention.
[0034] Fig.12 It is a curve diagram of serum mometasone furoate concentration during animal experiments with the drug delivery system according to the above preferred embodiment of the present invention.
[0035] Fig.13 4 is a degradation rate curve diagram of the animal experiment of the drug delivery system according to the above preferred embodiment of the present invention.
[0036] Fig.14 This is an electron micrograph of the freeze-dried drug-loaded hydrogel according to the eighth preferred embodiment of the present invention.
[0037] Fig.15 Graph 1 is a swelling curve of the drug loaded hydrogel according to the eighth preferred embodiment of the present invention.
[0038] Fig.16 These are the rheological characteristics of the drug-loaded hydrogel according to the eighth preferred embodiment of the present invention.
[0039] Fig.17 It is a characterization diagram of the synthetic degradable HA hydrogel and its molecular structure according to the above preferred embodiment of the present invention. DETAILED DESCRIPTION
[0040] The following description is used to disclose the present invention so that those skilled in the art can implement the present invention. The preferred embodiments described below are only examples, and those skilled in the art can think of other obvious variations. The basic principles of the present invention defined in the following description can be applied to other embodiments, variations, improvements, equivalents, and other technical solutions that do not deviate from the spirit and scope of the present invention.
[0041] At present, chronic sinusitis is a long-term chronic inflammation of the nasal sinus mucosa, which requires long-term treatment. The systemic use of hormones can lead to multiple side effects. Due to the cilia of the nasal mucosa, the hormones in the nasal spray are difficult to remain on the surface of the nasal mucosa for a long time, and the nasal spray cannot reach deep areas such as the frontal sinus.
[0042] Sodium hyaluronate has good biocompatibility with the extracellular matrix present in all vertebrate tissues and has multiple functions in wound healing. Studies have found that hyaluronic acid filling after sinus surgery helps the recovery of nasal epithelial mucosa. Sodium hyaluronate can not only remove reactive oxygen free radicals, promote the proliferation and migration of keratinocytes, but also accelerate the epithelialization of the mucosa after trauma. At the same time, the hyaluronic acid fragments produced by its degradation can also regulate the inflammatory response and stimulate angiogenesis. It is now widely used in rhinology, gynecology and other postoperative. However, although the hyaluronic acid gel currently used in clinical practice performs well in mucosal repair, it has no hemostatic effect. Therefore, a new type of gel hemostatic cotton (patch) is designed, which can not only have a hemostatic effect, but also can be used as a drug carrier at the same time, and has biocompatibility and a tailorable structural size. It is very necessary to place it in a specific part of the nasal cavity and sinuses to slowly release hormones to the local area for a long time.
[0043] There are many active groups in the structure of HA, which can be physically or chemically modified to prepare derivatives, making it a good carrier material for drug delivery. Therefore, a HA hydrogel with a new three-dimensional network structure is designed as a drug delivery system to prepare a new type of hemostatic sponge, which can take into account both hemostasis and more effective mucosal repair.
[0044] Therefore, the present invention adopts sodium hyaluronate gel as the three-dimensional network structure, and sodium carboxymethyl starch is filled in the network matrix and compounded with hyaluronic acid to finally form a hemostatic sponge with a three-dimensional network structure, so that it has high water absorption and achieves a better hemostatic effect. At the same time, it can deliver hormone drugs and slowly release hormone drugs to the lesion area. Since it is a local administration, compared with the traditional administration method, it effectively avoids systemic side effects.
[0045] The preparation method of the stepwise degradable drug-loaded hemostatic sponge of the present invention is as follows: A preparation method of the hemostatic sponge with a drug delivery system comprises the following steps:
[0046] (S10) preparing drug-loaded HA hydrogel;
[0047] (S20) preparing a hemostatic sponge composite structure pulp; and
[0048] (S30) preparing hemostatic sponge.
[0049] Embodiment 1:
[0050] The step (S10) comprises the following steps:
[0051] (S101) preparing a glucocorticoid nanoemulsion, i.e., a drug-loaded hydrogel liquid A; and
[0052] (S102) preparing a hydrogel mixture B having a drug-loaded three-dimensional network structure.
[0053] In the step (S101), 5 g of polyethylene glycol 400 is dissolved in 100 mL of distilled water as a cosolvent, and then 60 mg of mometasone furoate is added, and the mixture is stirred at 37° C. and 600 r / min until the mometasone furoate is completely dissolved to prepare liquid A.
[0054] The step (S102) comprises the following steps: (S0121) dissolving 5 g of sodium hyaluronate (HA) in 200 mL of distilled water and uniformly dispersing by ultrasonication; (S1022) slowly adding the solution A prepared in the step (S101) and stirring; (S1023) adding 2.5 g of carbodiimide after uniform stirring and magnetic stirring; and (S1024) magnetically stirring for 6-8 hours to prepare the drug-loaded hydrogel mixture B through chemical crosslinking.
[0055] The step (S20) comprises the following steps: (S201) dissolving 18 g of sodium carboxymethyl starch and 10 g of ethyl cellulose in 200 mL of distilled water; (S202) stirring evenly at 40-50° C., and then slowly pouring in liquid B; (S203) stirring evenly to allow the sodium carboxymethyl starch, carboxyethyl cellulose and sodium hyaluronate to form a three-dimensional network structure to form a hemostatic sponge composite structure pulp.
[0056] In the step (S30), the hemostatic sponge composite structure pulp prepared in the step (S20) is packed into plastic boxes, frozen at -20°C for 24 hours and then freeze-dried. 8 MPa is compressed into the required shape.
[0057] Embodiment 2:
[0058] The step (S10) comprises the following steps:
[0059] (S101) preparing drug-loaded hydrogel liquid A; and
[0060] (S102) preparing a hydrogel mixture B having a drug-loaded three-dimensional network structure.
[0061] In the step (S101), 5 g of polyethylene glycol 400 is dissolved in 100 mL of distilled water as a cosolvent, and then 60 mg of fluticasone propionate is added, and the mixture is stirred at 37° C. and 600 r / min until the fluticasone propionate is completely dissolved to prepare liquid A.
[0062] The step (S102) comprises the following steps: (S0121) dissolving 5 g of sodium hyaluronate (HA) in 200 mL of distilled water and uniformly dispersing by ultrasonication; (S1022) slowly adding the solution A prepared in the step (S101) and stirring; (S1023) adding 2.5 g of carbodiimide after uniform stirring and magnetic stirring; and (S1024) magnetically stirring for 6-8 hours to prepare the drug-loaded hydrogel liquid B through chemical crosslinking.
[0063] The step (S20) comprises the following steps: (S201) dissolving 18 g of sodium carboxymethyl starch and 10 g of ethyl cellulose in 200 mL of distilled water; (S202) stirring evenly at 40-50° C., and then slowly pouring in liquid B; (S203) stirring evenly to allow the sodium carboxymethyl starch, carboxyethyl cellulose and sodium hyaluronate to form a three-dimensional network structure to form a hemostatic sponge composite structure pulp.
[0064] In the step (S30), the hemostatic sponge composite structure pulp prepared in the step (S20) is packed into plastic boxes, frozen at -20°C for 24 hours and then freeze-dried. 8 MPa is compressed into the required shape.
[0065] Embodiment three:
[0066] The step (S10) comprises the following steps:
[0067] (S101) preparing drug-loaded hydrogel liquid A; and
[0068] (S102) preparing a hydrogel mixture B having a drug-loaded three-dimensional network structure.
[0069] In the step (S101), 5 g of polyethylene glycol 400 was dissolved in 100 mL of distilled water as a cosolvent, and then 60 mg of budesonide was added, and the mixture was stirred at 37° C. and 600 r / min until the budesonide was completely dissolved to prepare liquid A.
[0070] The step (S102) comprises the following steps: (S0121) dissolving 5 g of sodium hyaluronate (HA) in 200 mL of distilled water and uniformly dispersing by ultrasonication; (S1022) slowly adding the solution A prepared in the step (S101) and stirring; (S1023) adding 2.5 g of carbodiimide after uniform stirring and magnetic stirring; and (S1024) magnetically stirring for 6-8 hours to prepare the drug-loaded hydrogel liquid B through chemical crosslinking.
[0071] The step (S20) comprises the following steps: (S201) dissolving 18 g of sodium carboxymethyl starch and 10 g of ethyl cellulose in 200 mL of distilled water; (S202) stirring evenly at 40-50° C., and then slowly pouring in liquid B; (S203) stirring evenly to allow the sodium carboxymethyl starch, carboxyethyl cellulose and sodium hyaluronate to form a three-dimensional network structure to form a hemostatic sponge composite structure pulp.
[0072] In the step (S30), the hemostatic sponge composite structure pulp prepared in the step (S20) is packed into plastic boxes, frozen at -20°C for 24 hours and then freeze-dried. 8 MPa is compressed into the required shape.
[0073] Embodiment 4:
[0074] The step (S10) comprises the following steps:
[0075] (S101) preparing drug-loaded hydrogel liquid A; and
[0076] (S102) preparing a hydrogel mixture B having a drug-loaded three-dimensional network structure.
[0077] In the step (S101), 5 g of polyethylene glycol 600 is dissolved in 100 mL of distilled water as a cosolvent, and then 60 mg of mometasone furoate is added, and the mixture is stirred at 37° C. and 600 r / min until the mometasone furoate is completely dissolved to prepare liquid A.
[0078] The step (S102) comprises the following steps: (S0121) dissolving 5 g of sodium hyaluronate (HA) in 200 mL of distilled water and uniformly dispersing by ultrasonication; (S1022) after uniform dispersion, slowly adding the solution A prepared in the step (S101) and stirring; (S1023) after uniform stirring, adding 2.5 g of carbodiimide and magnetically stirring; and (S1024) magnetically stirring for 6-8 hours to prepare the drug-loaded hydrogel liquid B through chemical crosslinking.
[0079] The step (S20) comprises the following steps: (S201) dissolving 20 g of sodium carboxymethyl starch and 10 g of ethyl cellulose in 200 mL of distilled water; (S202) stirring evenly at 40-50° C., and then slowly pouring in liquid B; (S203) stirring evenly to allow the sodium carboxymethyl starch, carboxyethyl cellulose and sodium hyaluronate to form a three-dimensional network structure to form a hemostatic sponge composite structure pulp.
[0080] In the step (S30), the hemostatic sponge composite structure slurry prepared in the step (S20) is divided into 12 mL plastic boxes (each box contains 1.5 mg of mometasone furoate), frozen at -20°C for 24 hours and then freeze-dried. 8 MPa is compressed into the required shape.
[0081] Embodiment five:
[0082] The step (S10) comprises the following steps:
[0083] (S101) preparing drug-loaded hydrogel liquid A; and
[0084] (S102) preparing a hydrogel mixture B having a drug-loaded three-dimensional network structure.
[0085] In the step (S101), 5 g of polyethylene glycol 600 is dissolved in 100 mL of distilled water as a cosolvent, and then 60 mg of mometasone furoate is added, and the mixture is stirred at 37° C. and 600 r / min until the mometasone furoate is completely dissolved to prepare liquid A.
[0086] The step (S102) comprises the following steps: (S0121) dissolving 5 g of sodium hyaluronate (HA) in 300 mL of distilled water and uniformly dispersing by ultrasonication; (S1022) after uniform dispersion, slowly adding the solution A prepared in the step (S101) and stirring; (S1023) after uniform stirring, adding 2.5 g of carbodiimide and continuously magnetically stirring at 800 rpm; and (S1024) continuously magnetically stirring for 10 hours to prepare the drug-loaded hydrogel liquid B through chemical crosslinking.
[0087] The step (S20) comprises the following steps: (S201) dissolving 20 g of sodium carboxymethyl starch and 10 g of ethyl cellulose in 200 mL of distilled water; (S202) stirring evenly at 40-50° C., and then slowly pouring in liquid B; (S203) continuing magnetic stirring for 1 hour to allow the sodium carboxymethyl starch, carboxyethyl cellulose and sodium hyaluronate to form a three-dimensional network structure of hemostatic cotton.
[0088] In the step (S30), the hemostatic sponge composite structure slurry prepared in the step (S20) is divided into 12 mL plastic boxes (each box contains 1.5 mg of mometasone furoate), frozen at -20°C for 24 hours and then freeze-dried. 8 MPa is compressed into the required shape.
[0089] Embodiment six:
[0090] Wherein said step (S10) comprises the following steps:
[0091] (S101) preparing a glucocorticoid nanoemulsion, i.e., a drug-loaded hydrogel liquid A; and
[0092] (S102) preparing a hydrogel mixture B having a drug-loaded three-dimensional network structure.
[0093] In the step (S101), 5 g of polyethylene glycol 600 is dissolved in 100 mL of distilled water as a cosolvent, and then 60 mg of mometasone furoate is added, and the mixture is stirred at 37° C. and 600 r / min until the mometasone furoate is completely dissolved to prepare liquid A.
[0094] In the step (S102), 5 g of sodium thiohyaluronate is dissolved in 300 mL of distilled water and dispersed evenly by ultrasonication; the solution A prepared in the step (S101) is added to the sodium thiohyaluronate solution, and the drug-loaded hydrogel B is prepared by self-crosslinking of thiol / disulfide bonds.
[0095] The step (S20) comprises the following steps: (S201) dissolving 20 g of sodium carboxymethyl starch and 10 g of ethyl cellulose in 200 mL of distilled water; (S202) stirring evenly at 40-50° C., and then slowly pouring in liquid B; (S203) continuing magnetic stirring for 1 hour to allow the sodium carboxymethyl starch, carboxyethyl cellulose and sodium hyaluronate to form a three-dimensional network structure of hemostatic cotton.
[0096] In the step (S30), the hemostatic sponge composite structure slurry prepared in the step (S20) is divided into 12 mL plastic boxes (each box contains 1.5 mg of mometasone furoate), frozen at -20°C for 24 hours and then freeze-dried. 8 MPa is compressed into the required shape.
[0097] Embodiment seven:
[0098] The step (S101) comprises the following steps: (S1011) dissolving 11.67 g of adipic acid dihydrazine (ADH) in a HA (300 mL, 0.3 wt%) aqueous solution, and adjusting the solution pH to 5.35;
[0099] (S1012) dissolving 3 g of HA in 140 mL of distilled water, and then slowly adding the liquid obtained in step (S1011) after uniform ultrasonic dispersion;
[0100] (S1013) 1.5 g of EDC was added and magnetic stirring was performed for 7-8 h to prepare drug-loaded hydrogel liquid A through cross-linking.
[0101] The step (S102) includes the following steps:
[0102] (S1021) 0.2 g F127 and 30 mg mometasone furoate (MF) were dissolved in 10 mL PBS and then stirred in an ice water bath at 4°C until completely dissolved to prepare a F127-MF solution;
[0103] (S1022) Dissolving F127-MF in the drug-loaded hydrogel liquid A in step (S1013), and preparing the drug-loaded hydrogel mixed liquid B by magnetic stirring.
[0104] In the step (S20), 36 g of sodium carboxymethyl starch, 9 g of hydroxyethyl cellulose and 4.5 g of polyethylene glycol 400 are dissolved in 300 mL of distilled water, stirred evenly at 40-50° C., and then 150 mL of drug-loaded hydrogel liquid is slowly added and stirred evenly.
[0105] In the step (S30), the mixture is packaged into plastic boxes, frozen at -20°C for 24 hours, and then freeze-dried at -80°C. 8 MPa is compressed into the desired shape.
[0106] Embodiment eight:
[0107] The step (S10) comprises the following steps: (S1001) preparing oxidized hyaluronic acid; (S1002) preparing HA-ADH; and (S1003) preparing HA@F127-MF hydrogel.
[0108] In the step (S1001), 3g HA is dissolved in deionized water to prepare an aqueous solution (1wt%). Then 2g NaIO4 is added to the solution, reacted for 4 hours in a dark environment, 1mL ethylene glycol is added to terminate the reaction, and stirred for 2 hours. Deionized water is dialyzed for 3 days using a dialysis tube with a cut-off molecular weight of 3500Da. Oxidized hyaluronic acid (OHA) is obtained after freeze-drying.
[0109] In the step (S1002), the step (S1002) includes the following steps:
[0110] (A) 11.67 g of adipic acid dihydrazine (ADH) was dissolved in an aqueous solution of HA (300 mL, 0.3 wt%) to prepare solution A, and the pH of the solution was adjusted to 5.35;
[0111] (B) 1.725 g of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) and 1.215 g of 1-hydroxybenzotriazole (HOBT) were dissolved in a mixture of 1 mL of deionized water and 1 mL of dimethyl sulfoxide (DMSO), and the mixture was added to solution A. The pH value was adjusted to 5.0, reacted for 24 h, dialyzed in 0.1 M NaCl solution (pH = 3.5) for 48 h using a dialysis tube with a molecular weight cutoff of 8000-14000 Da, the dialyzed product was neutralized with 0.1 M NaOH solution, dialyzed in deionized water for 72 h, and freeze-dried for 3 days to obtain pure HA-ADH product.
[0112] (C) 0.2 g F127 and 30 mg mometasone furoate (MF) were dissolved in 10 mL PBS and then stirred in an ice-water bath at 4°C until completely dissolved to prepare a F127-MF solution. Subsequently, HA-ADH and OHA were dissolved in the F127-MF solution to form a HA-ADH solution (2% w / v) and an OHA solution (2% w / v), respectively. The two solutions were then mixed in a 1:1 ratio to form a HA@F127-MF hydrogel, which was prepared into a 150 mL liquid by adding deionized water.
[0113] In the above examples, the chemical methods for synthesizing the degradable HA hydrogel and characterizing the molecular structure are as follows Fig.17 As shown in A, the modified results are as follows Fig.17As shown in Figure B, OHA and HA-ADH form Schiff base bonds, which cross-link to form a self-healing and degradable HA@MF hydrogel. -1 and 1376cm -1 The absorption peaks of the CO bond are at 1645 cm -1 This indicates that the aldehyde group of OHA reacts with the amino group of HA-ADH to form an imine bond, indicating that HA modification is successful.
[0114] Specifically, the natural polymer HA was first modified to synthesize oxidized hyaluronic acid (OHA) and HA-adipic acid dihydrazide (ADH) ( Fig.17 A). The d-glucuronic acid hydroxyl group (-OH) of HA was oxidized by sodium periodate (NaIO4) to obtain OHA. The 1730 cm -1 The characteristic peaks of 1 H NMR further confirmed the aldehyde group of OHA ( Fig.17 Compared with HA, OHA in the range of 4.8-5.4 ppm 1 Three new chemical shifts appeared in H NMR, corresponding to the methylene groups adjacent to the aldehyde groups. The oxidation degree was calculated to be 32.69% by hydroxylamine hydrochloride titration. HA was reacted with ADH in the presence of 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) and 1-hydroxybenzotriazole (HOBt) to graft the hydrazide groups onto the HA polymer chain to generate HA-ADH. 1 The H NMR spectrum showed new peaks at 1.63 ppm and 2.32 ppm, indicating a grafting rate of 36.03%. The FTIR spectrum showed a peak at 1376 cm -1 The characteristic peak of carboxyl group increased significantly, indicating that ADH introduced amide group, resulting in the absorption peak of CO bond in n-acetylglucosamine residue at 1645cm -1 These results indicate that HA modification was successful.
[0115] The central polypropylene glycol segment of the poloxamer 407 (F127) molecule is relatively hydrophobic, while the polyethylene glycol segments at both ends are relatively hydrophilic. This amphiphilicity allows it to self-assemble into nanomicelles in water, which can be used to solubilize and load the hydrophobic drug MF. OHA solutions (labeled as solution A) and HA-ADH solutions (labeled as solution B) loaded with F127-MF were prepared. The mixture of solution A and solution B formed HA@F127-MF hydrogels through reversible dynamic Schiff base crosslinking between hydrazine and aldehyde groups.
[0116] The electron microscopy image of the drug-loaded hydrogel after freeze-drying prepared by the method of this embodiment is as follows Fig.14 As shown, it can be seen that it presents an obvious three-dimensional network structure, and has good swelling characteristics and rheological characteristics. Refer to the appendix Fig.15 and appendix Fig.16 .
[0117] Fig.15 Represents the microstructure, in vitro swelling and degradation properties, and MF sustained-release behavior of the hydrogel
[0118] The morphology of the hydrogel was observed by scanning electron microscopy (SEM), and the results are as shown in Fig.15 A in. The hydrogel has a heterogeneous, continuous and partially interconnected porous microstructure, similar to other natural macromolecular hydrogel systems. The in vitro release behavior of hydrogel MF is as shown in Fig.15 B in. F127 can effectively store hydrophobic MF, without obvious MF burst release, and continuously release about 79.4% within 14 days. The swelling ratio curve of the hydrogel is as shown in Fig.15 C in. After soaking in PBS for 8 h, the HA@F127-MF hydrogel reaches swelling equilibrium, and the swelling ratio is about 1500%, indicating the high water absorption capacity of the HA hydrogel. The degradation of the hydrogel was carried out in PBS ( Fig.15 D in), and the weight change of the hydrogel with time was measured. After 21 d, the remaining weight percentage of the HA@F127-MF hydrogel is 37.4%, indicating its good biodegradability.
[0119] Fig.16 The results of the rheological behavior analysis of the HA@F127-MF hydrogel are shown in Fig.16 A in shows that the scanning results with time indicate that the gel kinetic curve shows G′ greater than G″ in the initial stage; Fig.16 B in shows that in the frequency range of 0.1 - 100 hz, G′ is always greater than G″, indicating that the gel can maintain a stable network structure within a certain frequency range. The changes of G′ and G″ of the hydrogel at 0.01% - 100% strain were also measured ( Fig.16 C). The experimental results show that with the change of strain, the hydrogel changes from the "gel" state (G′>G″) to the "sol" state (G′<G″), and the strain at the intersection point is about 27%, indicating that the strain above this point can break most of the chemical cross-links in the hydrogel. According to the strain scanning results, 1% and 100% strain were selected as the strain parameters for the alternating strain scanning test.
[0120] The self-healing ability of the HA@F127-MF hydrogel was detected by the alternating strain scanning method, as shown in Fig.16 D in, Fig.16The D in the figure indicates that with the cyclic change of high / low strain, the hydrogel undergoes a corresponding "sol-gel" state transition; under high shear strain, the hydrogel is in a "sol" state. When the strain decreases, the hydrogel gradually recovers to a "gel" state through reversible dynamic crosslinking. After 3 cycles, the initial modulus of the hydrogel can be restored to about 95%. This is because the dynamic acylhydrazone bonds in the hydrogel break under high shear stress, and the hydrogel reorganizes after the high shear stress is removed, indicating that the hydrogel has good self-healing properties. In addition, Fig.16 As can be seen from E in the figure, the viscosity of HA@F127-MF hydrogel increases with the shear rate from 0.1 to 100 s -1 decreases with the increase of , indicating that the hydrogel has obvious shear thinning behavior.
[0121] The finished product of the stepwise degradable drug-loaded hemostatic sponge provided by the present invention is obtained by the above-mentioned embodiment. Figure 1 As shown, its performance test is as follows:
[0122] 1. Water absorption test
[0123] The step-by-step degradable drug-loaded hemostatic sponge provided by the present invention can absorb 16 mL of liquid within 12 seconds, and the liquid absorption rate is far superior to the hemostatic sponge currently known to be used in the market.
[0124] For specific comparison results, please refer to Figures 2 to 5 As shown, in Figure 2 In the experiment, two pieces of hemostatic sponges of the same size were placed in a culture dish for water absorption test, one of which was the stepwise degradable drug-loaded hemostatic sponge provided by the present invention, and was used as the experimental group; the other was the hemostatic sponge currently on the market, and was used as the control group.
[0125] like Figure 3 As shown, first inject 16 mL of water into a culture dish containing commercially available hemostatic sponge within three seconds, and then observe its water absorption.
[0126] like Figure 4 As shown, 16 mL of water was then injected into the culture dish of the experimental group of the stepwise degradable drug-loaded hemostatic sponge provided by the present invention. The water injection was also completed within three seconds, and the water absorption was observed.
[0127] like Figure 5 As shown, after 12 seconds, the hemostatic sponge in the experimental group completely absorbed 16 mL of water and expanded rapidly; at this time, the hemostatic sponge in the control group still contained more water. Since the control group added water first, it took more than 12 seconds to absorb less than 16 mL of water. It can be seen that the water absorption rate of the experimental group is higher.
[0128] It can be seen that the progressively degradable drug-loaded hemostatic sponge provided by the present invention has a high water absorption efficiency and a large expansion area, and can exert a large pressure on the nasal cavity wall in a short time. Therefore, it has a good hemostatic effect and is significantly better than the hemostatic sponge currently on the market.
[0129] 2. Electron microscope detection
[0130] pass Figure 6 and Figure 7 The results of electron microscopy showed that the structure of the degradable hemostatic sponge was a three-dimensional network structure, and sodium carboxymethyl starch and hydroxyethyl cellulose were composited on the three-dimensional network structure.
[0131] 3. Dissolution test of mometasone sulphonate
[0132] Take a certain amount of hemostatic sponge (about 1g) and put it into the dialysis bag, place the dialysis bag in 200mL of release medium (pH 6.2 phosphate buffer / ethanol = 80 / 20), and conduct in vitro release experiment at 37.0℃ with slow shaking. Take out 2mL at regular intervals at 6h, 12h, 1d, 2d, 3d, 4d, 5d, 6d, 8d, 10d, 12d, and 14d (and replace with the same volume of release medium), and use ultraviolet spectrophotometry to determine the released budesonide content at a wavelength of 254nm. The results of the in vitro dissolution experiment showed that mometasone furoate can be dissolved steadily and slowly. The dissolution results are shown in Figure 8 shown.
[0133] 4. Cell proliferation assay
[0134] Normal nasal mucosal epithelial cells were inoculated in a 96-well plate at 2000 cells / well and divided into an experimental group and a control group. Each group had 3 replicate wells and was cultured at 37°C and 5% CO2 for 6 hours. After the cells adhered to the wall, the experimental group was added with hemostatic sponge extract, and the control group was not added with any liquid. Each group of cells was incubated for 0h, 24h, and 48h. 2h before the end of incubation, 10μL of CCK8 solution was added to each well. After the incubation, OD450 was measured with an enzyme marker. The results showed that the hemostatic sponge had little effect on the proliferation of nasal mucosal epithelial cells. The experimental results are as follows: Fig. 9 shown.
[0135] 5. Animal experiments
[0136] Thirty SPF grade male SD rats weighing 300-400 g were selected. After general anesthesia, the nasal dorsum of the rats was disinfected, the bone was cut, the maxillary sinus was exposed, the mucosa in the sinus was preserved as much as possible, the lateral periosteal flap was raised from the midline to the right, a small hole with a diameter of about 1.5 mm was drilled, and the drug-loaded hemostatic sponge material (containing 0.08 mg of mometasone furoate) in the above embodiment was inserted into the maxillary sinus with ophthalmic forceps, the incision was sutured, and the animal experiment process was referred to Fig.10 .
[0137] On the 3rd, 6th, 9th, 12th and 15th days after surgery, 6 experimental rats were randomly selected, blood was collected from the heart, and the rats were killed to obtain the sinus mucosal tissue and the residual filling material in the sinus. The results are as follows Fig.11 and Fig.12 With the extension of time, the concentration of mometasone furoate gradually decreases with the degradable hemostatic sponge of the present invention as a carrier, indicating that the degradable hemostatic sponge of the present invention can be locally administered in a sustained-release manner and has a good therapeutic effect on patients with sinusitis.
[0138] The filling material was freeze-dried and weighed to calculate the degradation rate. The concentration of mometasone furoate in the serum and mucosal tissue of the experimental group rats was calculated by reversed-phase high performance liquid chromatography. The results are as follows: Fig.13 As shown, it is shown that the sinus drug-loaded hemostatic sponge has no adrenal inhibitory effect and has good biosafety and in vivo degradation rate.
[0139] In summary, the degradable hemostatic sponge prepared by the present invention has the following advantages:
[0140] Sodium hyaluronate gel is a three-dimensional network structure, and sodium carboxymethyl starch and hydroxyethyl cellulose are filled in the network and compounded with HA. After drying and compression, the three-dimensional network structure of the gel remains unchanged, and it has shape memory and high water absorption. In addition, dry starch is a capillary former, a hydrophilic substance with strong water absorption. After absorbing water, it can expand to 300 times its original volume, and expand rapidly. Therefore, the hemostatic sponge can exert a certain pressure on the wall of the surgical cavity, accelerate the concentration of red blood cells and platelets in the bleeding site, accelerate the endogenous coagulation process, and have a good hemostatic effect.
[0141] In terms of hormone drug delivery, rhinology currently uses nasal sprays, oral or injected drugs, which deliver drug molecules to the site of inflammation by systemic or local diffusion to reduce the expression of inflammatory factors and achieve the treatment of nasal inflammation, but there are various disadvantages. Since HA has a different degradation rate from carboxymethyl starch / hydroxyethyl cellulose, carboxymethyl starch / hydroxyethyl cellulose can be quickly degraded and discharged in a short period of time after sinus surgery, reducing the impact on sinus drainage, while HA has a slower degradation rate and HA has a drug-carrying effect. It can be seen from the above experiments that the degradable hemostatic sponge of the present invention is used as a carrier, and the drug is released slowly and controllably, indicating that the degradable hemostatic sponge in the present invention can achieve a better therapeutic effect by controlled sustained-release administration during the treatment of sinusitis after drug loading.
[0142] In terms of biological toxicity, the above experiments show that the hemostatic sponge of the present invention can be degraded in stages, and the degradation time of HA is long, so that it can be slowly and continuously administered locally for a long time, which plays a role in continuous anti-inflammatory, anti-adhesion, and promoting mucosal healing. Starch degradation speed is fast, and it can be degraded and liquefied within 1 week, while the three-dimensional network structure of sodium hyaluronate hydrogel can be partially retained in the surgical area and adhere to the mucosal surface of the surgical area, which plays a role in continuous anti-inflammatory, anti-adhesion, and promoting mucosal healing.
[0143] Hydroxyethyl cellulose is mainly used as an adhesive and also has a hemostatic effect. The hemostatic sponge can be compressed into a sheet, which is small and can be cut. It can expand quickly after absorbing liquid, which is convenient for filling the surgical area after surgery.
[0144] In addition, the compressed version of biodegradable nasal hemostatic sponge is small in size and can be cut.
[0145] In summary, those skilled in the art can understand that the degradable hemostatic sponge prepared by the method of the present invention is a three-dimensional network structure, which can facilitate postoperative nasal sinus packing, and has sustained-release drug delivery, is degradable, and can achieve better therapeutic effects, which is of great significance for the postoperative treatment of sinusitis.
[0146] It should be understood by those skilled in the art that the embodiments of the present invention described above and shown in the accompanying drawings are only examples and do not limit the present invention. The purpose of the present invention has been fully and effectively achieved. The functional and structural principles of the present invention have been demonstrated and explained in the embodiments, and the embodiments of the present invention may be deformed or modified in any way without departing from the principles.
Claims
1. A method for preparing a stepwise degradable drug-loaded hemostatic sponge, characterized in that: The following steps are involved: (S10) preparing drug-loaded HA hydrogel; (S20) preparing a hemostatic sponge composite structure pulp; and (S30) preparing hemostatic sponge.
2. The method for preparing the stepwise degradable drug-loaded hemostatic sponge according to claim 1, wherein the step (S10) comprises the following steps: (S101) preparing drug-loaded hydrogel liquid A; and (S102) preparing a drug-loaded three-dimensional network structured hydrogel mixed solution B, wherein in the step (S102), the solution A is added to a sodium thiol hyaluronate solution to prepare the drug-loaded hydrogel B through thiol / disulfide bond self-crosslinking.
3. The method for preparing the stepwise degradable drug-loaded hemostatic sponge according to claim 2, wherein in the step (S101), polyethylene glycol is added to distilled water, and then mometasone furoate, fluticasone propionate or budesonide is added, and stirred under ultrasound until completely dissolved to obtain a drug-loaded hydrogel liquid A; wherein the step (S102) comprises the following steps: (S0121) dissolving sodium hyaluronate in distilled water and dissolving evenly under ultrasound; (S1022) adding solution A prepared in step (S101) and stirring; (S1023) adding carbodiimide and stirring magnetically; and (S1024) stirring for a predetermined time to prepare a drug-loaded hydrogel mixture B through chemical cross-linking.
4. The method for preparing the stepwise degradable drug-loaded hemostatic sponge according to claim 2, wherein the step (S101) comprises the following steps: (S1011) dissolving adipic acid dihydrazine (ADH) in a HA aqueous solution and adjusting the pH; (S1012) dissolving HA in distilled water, ultrasonically dispersing and adding the liquid prepared in step (S1011); (S1013) adding 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC), and obtaining a drug-loaded hydrogel liquid A by cross-linking under magnetic stirring; The step (S102) comprises the following steps: (S1021) dissolving poloxamer 407 (F127) and mometasone furoate (MF) in PBS, and stirring in an ice-water bath to obtain an F127-MF solution; (S1022) dissolving F127-MF in the drug-loaded hydrogel liquid A in the step (S1013), and magnetically stirring to obtain a drug-loaded hydrogel mixed solution B.
5. The method for preparing the stepwise degradable drug-loaded hemostatic sponge according to claim 1, wherein the step (S10) comprises the following steps: (S1001) preparing oxidized hyaluronic acid; (S1002) preparing HA-ADH; And (S1003) preparing HA@F127-MF hydrogel.
6. The method for preparing the stepwise degradable drug-loaded hemostatic sponge according to claim 5, wherein in the step (S1001), HA is dissolved in deionized water to prepare a 1 wt% aqueous solution, and then NaIO4 is added to the solution, the reaction is carried out in the dark, ethylene glycol is added to terminate the reaction, the reaction is stirred, dialyzed, and freeze-dried to obtain oxidized hyaluronic acid (OHA); in the step (S1002), (A) adipic acid dihydrazide is dissolved in the aqueous solution of HA to prepare solution A, and (B) 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC), 1-hydroxy Benzotriazole is dissolved in a mixture of deionized water and dimethyl sulfoxide, and the mixture is added to solution A, reacted, dialyzed, and freeze-dried to obtain a pure HA-ADH product. In the step (S1003), poloxamer 407 (F127) and mometasone furoate (MF) are dissolved in PBS, stirred and dissolved in an ice water bath to prepare an F127-MF solution, and then HA-ADH and OHA are dissolved in the F127-MF solution respectively to form a HA-ADH solution and an OHA solution, and the two solutions are mixed in a ratio of 1:1 to form a HA@F127-MF hydrogel.
7. The method for preparing the stepwise degradable drug-loaded hemostatic sponge according to any one of claims 1 to 6, wherein the step (S20) comprises the following steps: (S201) dissolving sodium carboxymethyl starch and hydroxyethyl cellulose in distilled water; (S202) stirring evenly and pouring in liquid B; (S203) stirring to compound the three-dimensional network structure of sodium carboxymethyl starch, carboxyethyl cellulose and hyaluronic acid to form a hemostatic sponge composite structure slurry, wherein in the step (S30), the mixture is packaged into plastic boxes, frozen at -20°C for 24 hours, freeze-dried at -50°C to -80°C under vacuum conditions, and compressed into a desired shape under a predetermined pressure.
8. The method for preparing the stepwise degradable drug-loaded hemostatic sponge according to claim 7, wherein the mass ratio of polyethylene glycol to mometasone furoate is 1:12, the mass ratio of sodium hyaluronate to polyethylene glycol is 1:1, the mass ratio of carbodiimide to sodium hyaluronate is 1:2, the mass ratio of sodium carboxymethyl starch to carboxyethyl cellulose is 9:5, and the mass ratio of carboxyethyl cellulose to mometasone furoate is 1:
6.
9. A drug-loaded hemostatic sponge that can be degraded step by step, characterized in that: The step-by-step degradable drug-loaded hemostatic sponge is a drug-loaded hyaluronic acid hydrogel hemostatic sponge, and has a three-dimensional network structure, wherein the three-dimensional network structure is a hydrogel formed by cross-linking sodium hyaluronate, solution A, and carbodiimide through magnetic stirring for a predetermined time, or a drug-loaded hydrogel is prepared by self-crosslinking of thiol / disulfide bonds in thiol sodium hyaluronate, and the drug-loaded hydrogel is further compounded with sodium carboxymethyl starch and carboxyethyl cellulose to form a three-dimensional network composite structure pulp, wherein solution A is obtained by dissolving polyethylene glycol, distilled water, and mometasone furoate, fluticasone propionate, or budesonide under ultrasound, or oxidized hyaluronic acid and HA-ADH are dissolved in F127-MF to form a solution, and then mixed with HA@F127-MF hydrogel.
10. A drug-loaded hemostatic sponge that can be degraded step by step, characterized in that: The hemostatic sponge is prepared by the preparation method described in any one of claims 1 to 8.
Citation Information
Cited By
Hyaluronic acid hydrogel xylitol nasal spray and preparation method thereof
CN120078719A
